PSA (Prostate-Specific Antigen)
Screening Controversy, TRT Monitoring Role, and the Free/Total Ratio
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA-cleared tumor marker; screening use is guideline-contested (USPSTF shared decision-making for ages 55-69).
Reference only. Not medical advice.
What can go wrong
As a screen, PSA drives overdiagnosis and overtreatment of cancers that would never have caused harm - the core USPSTF concern. In TRT, skipping a baseline PSA can allow testosterone to be started in a man with occult prostate cancer, while over-reacting to transient elevations leads to unnecessary biopsy. A single number without free/total context and without controlling pre-analytic factors is easy to misread in either direction.
This is something to take to a clinician. The Atlas can tell you what is known about psa (prostate-specific antigen) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
PSA is a glycoprotein made by prostate epithelium; serum levels rise with prostate cancer but also with benign hyperplasia, prostatitis, and manipulation. As a population screening test it is contested - the USPSTF moved to shared decision-making (grade C) for men 55-69 after evidence of overdiagnosis and overtreatment, and recommends against routine screening at 70+. In the TRT context its role is narrower and more defensible: a baseline and on-therapy monitor, because testosterone can accelerate an occult prostate cancer. The free/total PSA ratio helps triage the 4-10 ng/mL gray zone: a lower percent-free favors cancer, a higher percent-free favors benign disease.
A contested screening test with a specific, defensible job in TRT monitoring.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Prostate cancer disrupts glandular architecture and raises serum PSA, but so do benign processes, which is why PSA lacks specificity. Free (unbound) PSA circulates at a higher proportion in benign conditions and a lower proportion in cancer, so the free/total ratio adds discrimination in the intermediate total-PSA range. In TRT, testosterone does not appear to cause prostate cancer, but because androgens can fuel an existing tumor, guidelines pair a baseline PSA with a DRE and periodic monitoring, especially in the first year.
The catch: the screening debate is not the monitoring debate
The population-screening controversy - overdiagnosis of indolent cancers - is a separate question from PSA's monitoring role in men starting testosterone. The marketplace tends to conflate them, either dismissing PSA entirely ('screening doesn't work') or over-reacting to a single mildly elevated value without accounting for recent ejaculation, prostatitis, BPH, or expected TRT-related change. Both errors are avoidable with baseline, repeat, and free/total context.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Baseline PSA and DRE before TRT
- Repeat PSA at 3-12 months and periodically thereafter
- Urology referral for confirmed rise or abnormal DRE
What people get wrong
Often saidA high PSA means cancer
ActuallyPSA rises with BPH, prostatitis, recent ejaculation, and even a recent exam. The free/total ratio and repeat testing are needed before conclusions.
Often saidTRT causes prostate cancer, so PSA proves the harm
ActuallyEvidence does not show TRT causes prostate cancer; PSA monitoring exists because androgens can fuel a pre-existing tumor, which is why baseline testing matters.
Often saidSince screening is controversial, PSA is useless on TRT
ActuallyIts monitoring role in men on testosterone is distinct from the population-screening debate and is guideline-endorsed.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- What it is
- Prostate epithelial glycoprotein / tumor marker
- Screening status
- USPSTF grade C (shared decision) ages 55-69; against routine at 70+
- Also raised by
- BPH, prostatitis, recent ejaculation, DRE, instrumentation
- TRT role
- Baseline then periodic monitoring on therapy
- Free/total ratio
- Low %-free favors cancer; high %-free favors benign (in the 4-10 range)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about PSA (Prostate-Specific Antigen). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
USPSTF prostate cancer screening recommendation2018
Moved to shared decision-making (grade C) for men 55-69 and recommended against routine screening at 70+, citing overdiagnosis
Catalona et al., free/total PSA studies1990s
Showed percent-free PSA improves cancer detection specificity in the 4-10 ng/mL range and reduces unnecessary biopsies
Endocrine Society and AUA TRT guidance on prostate monitoring2018
Recommend baseline PSA and DRE before TRT and periodic monitoring during therapy